Literature DB >> 12664588

Anti-leukotrienes as novel anti-inflammatory treatments in asthma.

Jeffrey M Drazen1.   

Abstract

The anti-leukotrienes are effective asthma treatments. This observation demonstrates, by inference, that leukotrienes are important in the biology of asthma. The clinical data also indicate, however, that the leukotrienes are not the sole mediator of asthmatic responses as patients with asthma are totally free of airway obstruction or asthma symptoms when they are treated with these agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12664588     DOI: 10.1007/978-1-4615-0193-0_33

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

1.  Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD.

Authors:  Jie Zhu; Venkata Bandi; Shengyang Qiu; David J Figueroa; Jilly F Evans; Neil Barnes; Kay K Guntupalli; Peter K Jeffery
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

2.  Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction.

Authors:  Sandra Tecklenburg-Lund; Timothy D Mickleborough; Louise A Turner; Alyce D Fly; Joel M Stager; Gregory S Montgomery
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

3.  Beta-catenin is involved in alterations in mitochondrial activity in non-transformed intestinal epithelial and colon cancer cells.

Authors:  M Mezhybovska; Y Yudina; A Abhyankar; A Sjölander
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

4.  Differential regulation of the release of tumor necrosis factor-alpha and of eicosanoids by mast cells in rat airways after antigen challenge.

Authors:  Aryene Goes Trezena; Zilma Lucia da Silva; Ricardo Martins Oliveira-Filho; Amilcar Sabino Damazo; Anita Hilda Straus; Helio Kiyoshi Takahashi; Sonia Maria Oliani; Wothan Tavares de Lima
Journal:  Mediators Inflamm       Date:  2003-08       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.